Literature DB >> 30643946

Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Matteo Bonatti1, Riccardo Valletta2,3, Giulia A Zamboni3, Fabio Lombardo2, Maria Senoner2, Mariachiara Simioni2,3, Guenther Schifferle2, Giampietro Bonatti2.   

Abstract

OBJECTIVES: To correlate the degree of ascites enhancement during hepatobiliary phase after gadobenate dimeglumine (Gd-BOPTA) administration with ascites aetiology.
METHODS: IRB-approved retrospective study, need for informed consent was waived. We included 74 consecutive ascitic patients who underwent Gd-BOPTA-enhanced liver MRI including hepatobiliary phase (HBP) images between January 2014 and December 2017. Ascites appearance on unenhanced and HBP images was classified as hypo-, iso- or hyperintense in comparison to paraspinal muscles. Ascites signal intensity on unenhanced and HBP images was measured using round ROIs and was normalised to paraspinal muscles (NSI). Normalised relative enhancement (NRE) between native phase and HBP was calculated. The results were related to ascites aetiology using Wilcoxon and Mann-Whitney tests.
RESULTS: On native images, ascites appeared hypointense in 95.9% of the cases and isointense in 4.1%, whereas on HBP images, it appeared hyperintense in 59.4% of the cases, isointense in 36.5% and hypointense in 4.1%. Mean ascites NSI was 0.52 on unenhanced images and 1.50 on HBP ones (p < 0.0001). Mean ascites NRE was 201 ± 133%. Ascites of non-malignant aetiology showed mean NRE of 210 ± 134%, whereas malignant ascites showed mean NRE of 92 ± 20% (p = 0.001). ROC analysis showed that a NRE < 112.5% correlates with malignant aetiology with 100% sensitivity and 83.4% specificity (LR = 5.667). NRE did not show any significant correlation with ascites thickness, eGFR and time interval between contrast administration and HBP acquisition (p > 0.05).
CONCLUSIONS: Ascites NRE in HBP after Gd-BOPTA administration is significantly lower in patients with ascites secondary to peritoneal carcinomatosis than in patients with non-malignant ascites. KEY POINTS: • Ascites enhancement in the hepatobiliary phase after Gd-BOPTA administration may determine false positive findings when looking for biliary leaks. • Ascites enhancement in the hepatobiliary phase after Gd-BOPTA administration is lower in patients with peritoneal carcinomatosis than in patients with portal hypertension or congestive heart failure. • None of the patients with peritoneal carcinomatosis showed an ascites enhancement of more than 112% as compared with unenhanced images.

Entities:  

Keywords:  Ascites; Gadobenate dimeglumine; Liver; Magnetic resonance imaging; Peritoneal neoplasms

Mesh:

Substances:

Year:  2019        PMID: 30643946     DOI: 10.1007/s00330-018-5932-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  20 in total

Review 1.  Mechanisms of ascites formation.

Authors:  A Cárdenas; R Bataller; V Arroyo
Journal:  Clin Liver Dis       Date:  2000-05       Impact factor: 6.126

Review 2.  Ascites: diagnosis and management.

Authors:  Wei Hou; Arun J Sanyal
Journal:  Med Clin North Am       Date:  2009-07       Impact factor: 5.456

3.  Advantages of gadobenate dimeglumine-enhanced MR cholangiography in the diagnosis of post-liver transplant bile leakage.

Authors:  M Fontarensky; P-F Montoriol; E Buc; L Poincloux; V Petitcolin; D Da Ines
Journal:  Diagn Interv Imaging       Date:  2013-02-19       Impact factor: 4.026

4.  Comparison of peritoneal tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values.

Authors:  Mahmut Bozkurt; Selim Doganay; Mecit Kantarci; Ahmet Yalcin; Suat Eren; S Selcuk Atamanalp; Ihsan Yuce; M Ilhan Yildirgan
Journal:  Eur J Radiol       Date:  2010-07-03       Impact factor: 3.528

Review 5.  Hepatobiliary MR imaging with gadolinium-based contrast agents.

Authors:  Alex Frydrychowicz; Meghan G Lubner; Jeffrey J Brown; Elmar M Merkle; Scott K Nagle; Neil M Rofsky; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-03       Impact factor: 4.813

6.  Cirrhotic and malignant ascites: differential CT diagnosis.

Authors:  J-R Risson; I Macovei; M Loock; B Paquette; M Martin; E Delabrousse
Journal:  Diagn Interv Imaging       Date:  2012-04-27       Impact factor: 4.026

Review 7.  Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.

Authors:  J T Tamsma; H J Keizer; A E Meinders
Journal:  Ann Oncol       Date:  2001-10       Impact factor: 32.976

8.  Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.

Authors:  Melanie K Seale; Onofrio A Catalano; Sanjay Saini; Peter F Hahn; Dushyant V Sahani
Journal:  Radiographics       Date:  2009-10       Impact factor: 5.333

9.  Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study.

Authors:  Russell N Low; Christopher P Sebrechts; Robert M Barone; Wayne Muller
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

10.  Delayed enhancement of ascites after i.v. contrast material administration at CT: time course and clinical correlation.

Authors:  Nancy Benedetti; Rizwan Aslam; Zhen J Wang; Bonnie N Joe; Yanjun Fu; Judy Yee; Benjamin M Yeh
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

View more
  2 in total

1.  Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.

Authors:  Shuwen Ji; Ziyong Wang; Shiyong Xia
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.